Keybank National Association OH Buys 5,434 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Keybank National Association OH grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 61.2% in the first quarter, according to its most recent filing with the SEC. The firm owned 14,315 shares of the medical equipment provider's stock after acquiring an additional 5,434 shares during the quarter. Keybank National Association OH's holdings in Zimmer Biomet were worth $1,620,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Brighton Jones LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter valued at $204,000. Proficio Capital Partners LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter valued at $55,000. SRS Capital Advisors Inc. lifted its holdings in shares of Zimmer Biomet by 146.9% during the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock valued at $51,000 after purchasing an additional 285 shares during the last quarter. Atria Investments Inc lifted its holdings in shares of Zimmer Biomet by 54.0% during the fourth quarter. Atria Investments Inc now owns 8,358 shares of the medical equipment provider's stock valued at $883,000 after purchasing an additional 2,929 shares during the last quarter. Finally, M&T Bank Corp raised its position in Zimmer Biomet by 0.4% during the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock valued at $2,834,000 after buying an additional 108 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on ZBH. Raymond James Financial dropped their target price on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley reduced their target price on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Wells Fargo & Company lowered their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Finally, Truist Financial set a $101.00 target price on Zimmer Biomet in a research report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and a consensus price target of $111.33.

Zimmer Biomet Price Performance

NYSE:ZBH traded up $0.17 during trading hours on Friday, reaching $93.67. 927,032 shares of the company were exchanged, compared to its average volume of 1,811,399. The company has a market capitalization of $18.53 billion, a P/E ratio of 20.72, a P/E/G ratio of 2.17 and a beta of 0.71. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. The business has a 50 day moving average of $94.04 and a 200 day moving average of $101.76.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The company had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the prior year, the company earned $1.94 EPS. Zimmer Biomet's revenue was up 1.1% compared to the same quarter last year. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's payout ratio is 21.24%.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.39% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.